![]() | |
Clinical data | |
---|---|
Routes of administration | PO |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C22H19N5O |
Molar mass | 369.428 g·mol−1 |
3D model ( JSmol) | |
| |
|
Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. [1] Development of galunisertib by Eli Lilly was discontinued in January 2020. [2]
Galunisertib was investigated in a phase II trial for treatment of hepatocellular carcinoma. [3] Pre-clinically, combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition. [4]
![]() | |
Clinical data | |
---|---|
Routes of administration | PO |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C22H19N5O |
Molar mass | 369.428 g·mol−1 |
3D model ( JSmol) | |
| |
|
Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. [1] Development of galunisertib by Eli Lilly was discontinued in January 2020. [2]
Galunisertib was investigated in a phase II trial for treatment of hepatocellular carcinoma. [3] Pre-clinically, combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition. [4]